Post-infectious disorder

Summary

Post-infectious disorder (MONDO:0021669) is a disease (an umbrella term covering 14 Mondo subtypes) and 2 clinical trials. A subtype of disease of primarily extrinsic mechanism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 14 Mondo subtypes
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	post-infectious disorder
Mondo ID	MONDO:0021669
ICD-10-CM	B90-B94
SNOMED CT	123976001
UMLS	C1264603
MedGen	688819
Is cancer (heuristic)	no

Also known as: sequela of infectious disorder

Disease family

An umbrella term covering 14 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › post-infectious disorder

Related subtypes (6): infectious disease, poisoning, radiation-induced disorder, iatrogenic disease, occupational disorder, disease related to transplantation

Subtypes (14): encephalopathy, acute, infection-induced, infective urethral stricture, infectious otitis interna, otitis externa, infected hydrocele, Chagas cardiomyopathy, postinfectious vasculitis, postinfectious encephalitis, post-infectious syndrome, post-bacterial disorder, post-viral disorder, infection-related hemolytic uremic syndrome, infectious neuropathy, infection-induced acute-onset axonal neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04846010	PHASE1/PHASE2	UNKNOWN	Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
NCT06085911	Not specified	UNKNOWN	RCT Long COVID-19 Rehabilitation